NO20054476L - Forbindelser for behandling av smerte - Google Patents

Forbindelser for behandling av smerte

Info

Publication number
NO20054476L
NO20054476L NO20054476A NO20054476A NO20054476L NO 20054476 L NO20054476 L NO 20054476L NO 20054476 A NO20054476 A NO 20054476A NO 20054476 A NO20054476 A NO 20054476A NO 20054476 L NO20054476 L NO 20054476L
Authority
NO
Norway
Prior art keywords
compounds
pain
treatment
antihyperalgesics
analgesics
Prior art date
Application number
NO20054476A
Other languages
English (en)
Other versions
NO20054476D0 (no
Inventor
Peter Richardson
Kevin Lee
Lisa Lione
Original Assignee
Cambridge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd
Publication of NO20054476D0 publication Critical patent/NO20054476D0/no
Publication of NO20054476L publication Critical patent/NO20054476L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)

Abstract

Anvendelse av forbindelser med formel (I) der R er C1-4 alkoksy og X er H eller OH, som analgetika og særlig antihyperalgetika.
NO20054476A 2003-03-07 2005-09-27 Forbindelser for behandling av smerte NO20054476L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0305149.7A GB0305149D0 (en) 2003-03-07 2003-03-07 Compounds for the treatment of pain
PCT/GB2004/000935 WO2004078183A1 (en) 2003-03-07 2004-03-05 Compounds for the treatment of pain

Publications (2)

Publication Number Publication Date
NO20054476D0 NO20054476D0 (no) 2005-09-27
NO20054476L true NO20054476L (no) 2005-11-24

Family

ID=9954247

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054476A NO20054476L (no) 2003-03-07 2005-09-27 Forbindelser for behandling av smerte

Country Status (19)

Country Link
US (1) US7759321B2 (no)
EP (1) EP1603577B1 (no)
JP (1) JP2006519823A (no)
KR (1) KR20050115273A (no)
CN (1) CN100579533C (no)
AT (1) ATE401087T1 (no)
AU (1) AU2004216889B2 (no)
CA (1) CA2514098A1 (no)
CY (1) CY1108416T1 (no)
DE (1) DE602004015085D1 (no)
DK (1) DK1603577T3 (no)
ES (1) ES2310288T3 (no)
GB (1) GB0305149D0 (no)
NO (1) NO20054476L (no)
NZ (1) NZ541521A (no)
PL (1) PL1603577T3 (no)
PT (1) PT1603577E (no)
SI (1) SI1603577T1 (no)
WO (1) WO2004078183A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
GB0305150D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
MXPA06010075A (es) * 2004-03-05 2007-04-10 Cambridge Biotechnology Ltd Compuestos terapeuticos.
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CN1947717B (zh) * 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US7807685B2 (en) 2006-06-27 2010-10-05 Cbt Development Limited Therapeutic compounds
ES2361886T3 (es) 2006-06-27 2011-06-24 Cbt Development Limited Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina.
CA2654371A1 (en) 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Therapeutic compounds
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
CN103342727A (zh) * 2013-07-01 2013-10-09 淮海工学院 一种2-甲氧基腺苷的合成方法
JP6440240B2 (ja) * 2014-02-19 2018-12-19 国立大学法人富山大学 末梢神経障害誘発感覚異常を改善する外用剤
CN114616230A (zh) * 2019-07-31 2022-06-10 海洋生物技术与海洋资源有限公司 黄烷类似物化合物及其在治疗慢性和急性疼痛中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792155A (fr) 1971-12-01 1973-05-30 Takeda Chemical Industries Ltd Nouveaux derives de l'adenosine et leur procede de production
JPS4861498A (no) 1971-12-01 1973-08-28
DE2359536C2 (de) 1972-12-08 1984-08-02 Takeda Chemical Industries, Ltd., Osaka 2,6-Diaminonebularinderivate
JPS5461195A (en) 1977-10-21 1979-05-17 Takeda Chem Ind Ltd N2-substituted phenyl-2,6-diaminonebularin
JPS5461194A (en) 1977-10-21 1979-05-17 Takeda Chem Ind Ltd Preparation of n22substituted 2*66diaminonebularin
US4705758A (en) 1984-06-19 1987-11-10 Warner-Lambert Company Adenosine receptor assay and kit
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5683989A (en) * 1993-12-17 1997-11-04 Novo Nordisk A/S Treatment of ischemias by administration of 2,N6 -substituted adenosines
FI964468A0 (fi) * 1994-05-10 1996-11-06 Sandoz Ltd Adenosiinijohdannaisia
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
IT1275420B (it) 1995-06-02 1997-08-05 Schering Plough S P A Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
EP1044004A1 (en) 1998-01-08 2000-10-18 The University Of Virginia Patent Foundation A2a adenosine receptor agonists in combination with a type iv phosphodiesterase inhibitors
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds

Also Published As

Publication number Publication date
KR20050115273A (ko) 2005-12-07
US20070066559A1 (en) 2007-03-22
AU2004216889A1 (en) 2004-09-16
DK1603577T3 (da) 2008-11-17
NO20054476D0 (no) 2005-09-27
PL1603577T3 (pl) 2009-01-30
DE602004015085D1 (de) 2008-08-28
CA2514098A1 (en) 2004-09-16
NZ541521A (en) 2008-09-26
EP1603577A1 (en) 2005-12-14
PT1603577E (pt) 2008-10-23
ES2310288T3 (es) 2009-01-01
WO2004078183A1 (en) 2004-09-16
AU2004216889B2 (en) 2009-06-11
CY1108416T1 (el) 2013-09-04
SI1603577T1 (sl) 2008-12-31
EP1603577B1 (en) 2008-07-16
CN100579533C (zh) 2010-01-13
US7759321B2 (en) 2010-07-20
CN1750835A (zh) 2006-03-22
HK1087629A1 (zh) 2006-10-20
GB0305149D0 (en) 2003-04-09
JP2006519823A (ja) 2006-08-31
ATE401087T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
DE60112974D1 (en) Carbolinderivate
NO20050065L (no) Kjemiske forbindelser
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
MXPA03007142A (es) Derivados de carbolina.
NO20064365L (no) Terapeutisk forbindelse
NO20034661D0 (no) Nociceptin-analoger
MXPA03012013A (es) Derivados de 1-oxa-2,8-diaza-spiro[4,5]dec-2-eno sustituidos como medicamento para el tratamiento de dolor.
DE60143906D1 (de) Verwendung von derivaten der 2-oxothiazolidin-4-corbonsäure als prä-abschuppungsmittel
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
MXPA05012247A (es) Derivados de bencimidazol nuevos.
MXPA02012076A (es) Compuestos quimicos.
GB0127903D0 (en) Improvements relating to organic compounds
MXPA03002911A (es) Compuestos quimicos.
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
MXPA02012659A (es) Derivados de pirazindiona condensados.
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
PL376324A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
HRP20090159T1 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
NO20033959D0 (no) Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon
PT1419163E (pt) Imidazopiridinas triciclicas
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
GB0229081D0 (en) Multifunctional cationic photoinitiators, their preparation and use
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
MXPA02012472A (es) Compuestos quimicos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application